DOCSLIB.ORG

Topical Corticosteroids Post Limit PA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topical Corticosteroids Post Limit PA Topical Corticosteroids Post Limit PA PHYSICIAN PRIOR AUTHORIZATION REQUEST FORM Patient Information Name: Member ID #: Group Name: Date of Birth: Diagnosis: Diagnosis Code: Provider Information Prescriber’s Name: Prescriber’s DEA #: Phone Number: Fax Number: Office Address: Complete and review information, sign and date. Fax signed form to Caremark’s Prior Authorization department at 888-836-0730. Caremark is an independent company that provides pharmacy benefit management services, including prior authorization review, on behalf of the member’s health plan. The Caremark fax machine is located in a secure location as required by HIPAA regulations. Providers can call Caremark at 800-294-5979 with any questions concerning prior authorization procedures. Members should call Caremark Customer Care at 888-963-7290 with any questions. Members can also call their health plan at the number on their member ID cards. 1. Is the requested drug being prescribed for a corticosteroid-responsive dermatosis or condition Yes No (e.g., eczema, atopic dermatitis, seborrheic dermatitis, psoriasis)? 2. Which drug is being requested (applies to brand or generic)? [Note: Please check which drug (applies to brand or generic).] [] Aclovate (alclometasone) (if checked, go to 3) [] Ala-Scalp (hydrocortisone) (if checked, go to 4) [] Alclometasone (if checked, go to 3) [] Amcinonide (if checked, go to 5) [] Apexicon E (diflorasone diacetate) (if checked, go to 6) [] Betamethasone Dipropionate (if checked, go to 7) [] Betamethasone Valerate (if checked, go to 7) [] Bryhali (halobetasol) (if checked, go to 16) [] Clobex (clobetasol) (if checked, go to 8) [] Cloderm (clocortolone) (if checked, go to 17) [] Cordran (flurandrenolide) (if checked, go to 9) [] Cutivate (fluticasone) (if checked, go to 10) [] Dermatop (prednicarbate) (if checked, go to 17) [] Desonate (desonide) (if checked, go to 11) [] Desonide (if checked, go to 11) [] DesOwen (desonide) (if checked, go to 11) [] Diflorasone (if checked, go to 6) [] Diprolene, Diprolene AF (betamethasone dipropionate augmented) (if checked, go to 7) [] Elocon (mometasone) (if checked, go to 12) [] Fluocinolone (if checked, go to 13) [] Fluocinonide (if checked, go to 14) [] Fluticasone (if checked, go to 10) [] Halog (halcinonide) (if checked, go to 17) [] Hydrocortisone, Hydrocortisone Valerate (if checked, go to 4) Confidential Page 1 of 3 Effective: 04/01/19 [] Impoyz (clobetasol) (if checked, go to 8) [] Locoid, Locoid Lipocream (hydrocortisone butyrate) (if checked, go to 4) [] LoKara (desonide) (if checked, go to 11) [] MiCort HC (hydrocortisone acetate) (if checked, go to 4) [] Nolix (flurandrenolide) (if checked, go to 9) [] Pandel (hydrocortisone probutate) (if checked, go to 4) [] Psorcon (diflorasone) (if checked, go to 6) [] Synalar (fluocinolone) (if checked, go to 13) [] Temovate, Temovate E (clobetasol) (if checked, go to 8) [] Topicort (desoximetasone) (if checked, go to 17) [] Triamcinolone (if checked, go to 15) [] Trianex (triamcinolone) (if checked, go to 15) [] Tridesilon (desonide) (if checked, go to 11) [] Ultravate (halobetasol) (if checked, go to 16) [] Vanos (fluocinonide) (if checked, go to 14) [] Westcort (hydrocortisone valerate) (if checked, go to 4) 3. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 240 grams of Aclovate (alclometasone) cream, B) 240 grams of alclometasone ointment? [No further questions.] 4. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 240 milliliters of Ala-Scalp (hydrocortisone) lotion, B) 180 grams of Locoid (hydrocortisone butyrate) cream or ointment, C) 180 grams of Locoid Lipocream (hydrocortisone butyrate), D) 180 milliliters of Locoid (hydrocortisone butyrate) lotion, E) 240 grams of MiCort HC (hydrocortisone acetate) cream, F) 160 grams of Pandel (hydrocortisone probutate), G) 180 grams of Westcort (hydrocortisone valerate) ointment, H) 240 grams of hydrocortisone cream or ointment, I) 240 milliliters of hydrocortisone lotion, J) 180 grams of hydrocortisone valerate cream? [No further questions.] 5. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 180 grams of amcinonide cream or ointment, B) 180 milliliters of amcinonide lotion? [No further questions.] 6. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 180 grams of Apexicon E (diflorasone diacetate) emollient cream, B) 180 grams of Psorcon (diflorasone) cream, C) 180 grams of diflorasone ointment? [No further questions.] 7. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 150 grams of Diprolene (betamethasone dipropionate augmented) ointment, B) 150 grams of Diprolene AF (betamethasone dipropionate augmented) cream, C) 180 milliliters of Diprolene (betamethasone dipropionate augmented) lotion, D) 150 grams of betamethasone dipropionate augmented gel, D) 150 grams of betamethasone dipropionate unaugmented cream or ointment, E) 180 milliliters of betamethasone dipropionate unaugmented lotion, F) 150 grams of betamethasone valerate cream or ointment, F) 180 milliliters of betamethasone valerate lotion? [No further questions.] 8. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 180 milliliters of Clobex (clobetasol) lotion, B) 180 grams of Impoyz (clobetasol), C) 180 grams of Temovate (clobetasol), D) 180 grams of Temovate E (clobetasol emollient)? [No further questions.] 9. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 240 grams of Cordran (flurandrenolide) cream, B) 240 milliliters of Cordran (flurandrenolide) lotion, C) 180 grams of Cordran (flurandrenolide) ointment, D) 240 grams of Nolix (flurandrenolide) cream, E) 240 milliliters of Nolix (flurandrenolide) lotion? [No further questions.] Confidential Page 2 of 3 Effective: 04/01/19 10. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 150 grams of Cutivate (fluticasone) cream, B) 240 milliliters of Cutivate (fluticasone) lotion, C) 150 grams of fluticasone ointment? [No further questions.] 11. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 240 grams of Desonate (desonide) gel, B) 240 grams of DesOwen (desonide) cream, C) 240 milliliters of DesOwen (desonide) lotion, D) 240 milliliters of LoKara (desonide), E) 240 grams of Tridesilon (desonide), F) 240 grams of desonide ointment? [No further questions.] 12. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 150 grams of Elocon (mometasone) cream, B) 150 grams of Elocon (mometasone) ointment, C) 180 milliliters of Elocon (mometasone) lotion? [No further questions.] 13. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 240 grams of Synalar (fluocinolone) 0.025 percent cream or ointment, B) 240 grams of fluocinolone 0.01 percent cream? [No further questions.] 14. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 150 grams of Vanos (fluocinonide 0.1 percent), B) 150 grams of fluocinonide 0.05 percent cream, emulsified base cream, gel or ointment? [No further questions.] 15. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 430 grams of Trianex (triamcinolone), B) 160 grams of triamcinolone 0.025 percent cream or ointment, C) 160 grams of triamcinolone 0.1 percent cream or ointment, D) 150 grams of triamcinolone 0.5 percent cream or ointment, E) 180 milliliters of triamcinolone lotion? [No further questions.] 16. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 180 grams of Bryhali (halobetasol) lotion, B) 150 grams of Ultravate (halobetasol) cream, C) 180 milliliters of Ultravate (halobetasol) lotion, D) 150 grams of Ultravate (halobetasol) ointment? [No further questions.] 17. Does the patient require more than the plan allowance PER MONTH of one of the following: A) Yes No 150 grams of Cloderm (clocortolone) cream, B) 180 grams of Dermatop (prednicarbate) cream or ointment, C) 150 grams of Halog (halcinonide) cream or ointment, D) 180 grams of Topicort cream, gel, or ointment? Comments: _______________________________________________________________________________________ Information on this form is accurate as of this date. Prescriber’s Signature: Date: Confidential Page 3 of 3 Effective: 04/01/19 .
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • 120.Clobetasol Propionate and [email protected]
    IAJPS 2017, 4 (10), 3779-3786 Harikishor Barange et al ISSN 2349-7750 CODEN (USA): IAJPBB ISSN: 2349-7750 INDO AMERICAN JOURNAL OF PHARMACEUTICALSCIENCES Available online at: http://www.iajps.com Research Article DEVELOPMENT OF ANALYTICAL METHOD AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF CLOBETASOL PROPIONATE AND KETOCONAZOLE IN PHARMACEUTICAL CREAM FORMULATION BY RP-HPLC METHOD Harikishor Barange*, Suhail Asghar and Pooja Gour Unijules Life Sciences Ltd., B - 35, 36 MIDC Area Kalmeshwar Nagpur – 441501, Maharashtra, India. E-mail of Corresponding author: [email protected]. Abstract: A simple, accurate rapid and precise has been developed and validated for simultaneous estimation of Clobetasol Propionate and Ketoconazole in Pharmaceutical Cream Formulation by RP-HPLC Method. The successful estimation was carried out of the drug product is developed on the ODS Qualisil Column C18 (250 mm x 4.6 mm, 5μm or equivalent) at ambient temperature using Methanol: Acetonitrile: Phosphate buffer (50:20:30 v/v/v) as mobile phase composition. The flow rate was adjusted to 1.5mL/minute and the absorption maxima were observed on UV detector at 254 nm. Retention Time for Clobetasole Propionate 11.1±0.1min and Ketoconazole 12.2±0.1min. The linearity was obtained in the concentration range of 6-14µg/mL and 120-280µg/mL for Clobetasole Propionate and Ketoconazole respectively. Mean percentage recoveries were 99.16% for Clobetasole Propionate and 99.17% for Ketoconazole. The LOD of Clobetasole Propionate and Ketoconazole were found to be 0.7μg/mL and 2.0μg/mL whereas the LOQ was 3.0μg/mL and 10.0μg/mL respectively. Percentage relative standard deviation of percent assay values for replicate sample preparation was 0.28% for Clobetasole Propionate and 0.47% for Ketoconazole.
    [Show full text]
  • A List of Medications That May Lower Your Patients' Costs
    A list of medications that may lower your patients’ costs INTRODUCTION Catamaran utilizes a Pharmacy and Therapeutics Committee (P & T Committee), made up of practicing physicians, pharmacists, and nurses to help ensure that our formulary is medically sound and that it supports patient health. This committee reviews and evaluates medications on the formulary based on safety and efficacy to help maintain clinical integrity in all therapeutic categories. FORMULARY DESIGN There are numerous formulary designs that can be used by a pharmacy benefits administrator. Catamaran has chosen a formulary structure which is open and incentive based. Open Formulary: features co‐payments for medications that are preferred and non‐ preferred brands, plus lower co‐payments for generic drugs. Incentive Based: features different co‐payments for medications that are on or off the formulary. In this type of formulary, the patient cost structure may be two‐tier, three‐ tier, or four‐tier design. USING THIS FORMULARY REFERENCE GUIDE TO HELP CONTAIN COSTS Many benefit sponsors use the Catamaran formulary to help manage the overall cost of providing prescription drug benefits. This formulary offers a wide range of medications from which to choose. We realize that this formulary reference guide may not include every drug from every manufacturer. However, choosing a preferred drug when it is appropriate can provide access to the necessary medications to stay healthy, at a cost that is more affordable. KNOWING HOW THE FORMULARY INFORMATION IS ORGANIZED The following formulary reference guide is designed so that generic products are listed first in each drug category. The preferred brand name products are listed next, and non‐preferred brand products are listed last.
    [Show full text]
  • Wo 2008/127291 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 23 October 2008 (23.10.2008) WO 2008/127291 A2 (51) International Patent Classification: Jeffrey, J. [US/US]; 106 Glenview Drive, Los Alamos, GOlN 33/53 (2006.01) GOlN 33/68 (2006.01) NM 87544 (US). HARRIS, Michael, N. [US/US]; 295 GOlN 21/76 (2006.01) GOlN 23/223 (2006.01) Kilby Avenue, Los Alamos, NM 87544 (US). BURRELL, Anthony, K. [NZ/US]; 2431 Canyon Glen, Los Alamos, (21) International Application Number: NM 87544 (US). PCT/US2007/021888 (74) Agents: COTTRELL, Bruce, H. et al.; Los Alamos (22) International Filing Date: 10 October 2007 (10.10.2007) National Laboratory, LGTP, MS A187, Los Alamos, NM 87545 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY,BZ, CA, CH, (30) Priority Data: CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, 60/850,594 10 October 2006 (10.10.2006) US ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicants (for all designated States except US): LOS LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, ALAMOS NATIONAL SECURITY,LLC [US/US]; Los MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, Alamos National Laboratory, Lc/ip, Ms A187, Los Alamos, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, NM 87545 (US).
    [Show full text]
  • Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Seborrheic Dermatitis
    Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Seborrheic Dermatitis Diagnosis: SEBORRHEIC DERMATITIS GENERAL INFORMATION: • Seborrheic dermatitis is a common, benign skin condition that is thought to be caused by overgrowth of a yeast that resides on the skin, Malassezia. • In infants, this typically resolves within the first year of life, so treatment is not required. • In children and teenagers, this may be chronic, requiring maintenance therapy. TREATMENT RECOMMENDATIONS: For children/teenagers: Scalp: • Maintenance shampoo 2-3 times weekly (or less frequently for drier hair types), shampoo should be allowed to sit for ~5 minutes before rinsing) o Ketoconazole 2% shampoo o OTC Selenium sulfide shampoos (Selsun Blue, Head and Shoulders Clinical Strength) o OTC Pyrithione zinc shampoos (Head and Shoulders Classic Clean) • For symptomatic relief: Fluocinolone 0.01% (Derma smoothe oil) or clobetasol 0.05% solution twice daily as needed. Face: • Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with hydrocortisone 2.5% cream (or other class 5, 6, 7 topical steroid) For infants with generalized skin involvement • Mild: Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with hydrocortisone 2.5% ointment (or other class 5, 6, 7 topical steroid) • Severe: Miconazole 1 % cream (or other anti-yeast medication) mixed in equal amounts with triamcinolone 0.1% ointment (or other class 3 or 4 topical steroid) REFERRAL GUIDELINES: Please refer patients who fail treatment guidelines above. Please avoid referring patients who are frustrated by need for maintenance therapy, as this is expected. Educational recommendations are made from the best evidence, expert opinions and consideration for the patients and families cared for by the service.
    [Show full text]
  • 2021 Comprehensive Formulary  (List of Covered Drugs) Pima Pinal  Maricopa
    2021 Comprehensive Formulary (List of Covered Drugs) Pima Pinal Maricopa PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN 21026 Version 01. This formulary was updated on 05/01/2021. For more recent information or other questions, please contact Banner Plus at (844) 549-1859 or, for TTY users, 711, 8 a.m. to 8 p.m.,7 days a week, or visit www.BannerMA.com. Banner Medicare Advantage Plus PPO H7273_ComprehensiveFormularyCY21_C Banner Medicare Advantage Plus 2021 Comprehensive Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN 21026 Version Number 01 This formulary was updated on 05/01/2021. For more recent information or other questions, please contact Banner Medicare Advantage Plus at (844) 549-1859 or, for TTY users, 711, 8 a. m. to 8 p. m., 7 days a week, or visit www.BannerMA.com. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Banner Medicare Advantage Plus. When it refers to “plan” or “our plan,” it means Banner Medicare Advantage Plus PPO. This document includes a list of the drugs (formulary) for our plan which is current as of May 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit.
    [Show full text]
  • Asian Journal of Chemistry Asian Journal of Chemistry
    Asian Journal of Chemistry; Vol. 26, No. 18 (2014), 6043-6046 ASIAN JOURNAL OF CHEMISTRY http://dx.doi.org/10.14233/ajchem.2014.16548 Microbial Transformation of Topical Corticosteroid: Prednicarbate 1,* 1 1 1 2 SAEED AHMAD , MUHAMMAD FAHAD MUKHTAR , FARHAN HAMEED KHALIQ , SAJID IRSHAD and JAVED IQBAL 1Faculty of Pharmacy and Alternative Medicine, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan 2Faculty of Pharmacy, University of Lahore, Lahore 54000, Pakistan *Corresponding author: Tel: +92 62 9255243; E-mail: [email protected] Received: 19 October 2013; Accepted: 29 November 2013; Published online: 1 September 2014; AJC-15850 In the present research, the steroidal antiinflammatory topically used drug prednicarbate (1) was subjected to microbial biotransformation by Cunninghamella elegans. Prednicarbate (1) was transformed into various metabolites. One new and two known metabolites were purified named as prednisolone 17-ethylcarbonate (2) Prednisolone (3) and 4-(4-hydroxybenzyl)-2-(3-methylbut-2-enyl)phenyl methyl carbonate (4). The compound (4) was separated as a new compound and was not reported in literature. Its structure did not show resemblance with prednicarbate so possibly derived from fungal mass. Their structures were elucidated by using modern spectroscopic techniques e.g. 13C NMR, 1H NMR, HMQC, HMQC, COSY, NOESY and mass spectrometry e.g. EI-MS. Keywords: Biotransformation, Cunninghamella elegans, Prednicarbate, Topical. INTRODUCTION EXPERIMENTAL Now a day's microbial biotransformation is flourished in Prednicarbate (1) was obtained from Stiefel Laboratories order to find the new modified drug molecules. In microbes, Pakistan (Pvt) Ltd. Thin layer chromatography was carried bacteria and fungi are used to modify existing drug molecules out on precoated plates (Silica gel, Merck, PF254).
    [Show full text]
  • WO 2016/196365 Al 8 December 2016 (08.12.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/196365 Al 8 December 2016 (08.12.2016) P O P C T (51) International Patent Classification: (72) Inventors: GARCIA, Andres; 3717 Bentley Drive, A61F 9/01 (2006.01) A61L 27/54 (2006.01) Durham, North Carolina 27707 (US). VERHOEVEN, A61K 9/00 (2006.01) A61L 27/58 (2006.01) Rozemarijn Suzanne; 27 Hillcrest Drive, Pittsboro, North A61K 47/10 (2006.01) Carolina 273 12 (US). NAVRATIL, Tomas; 706 West Main Street, Carrboro, North Carolina 275 10 (US). (21) International Application Number: SCHIFFMAN, Rhett; c/o Envisia Therapeutics, Inc., 419 PCT/US20 16/034820 Davis Drive, Suite 100, Morrisville, North Carolina 27560 (22) International Filing Date: (US). 27 May 2016 (27.05.2016) (74) Agents: COUSIN, Jonathan M. et al; 1299 Pennsylvania (25) Filing Language: English Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/168,292 29 May 2015 (29.05.2015) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 62/206,535 18 August 2015 (18.08.2015) US BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, 62/260,964 30 November 2015 (30. 11.2015) us DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/329,769 29 April 2016 (29.04.2016) us HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (71) Applicant: ENVISIA THERAPEUTICS, INC.
    [Show full text]